Swen Wessendorf

Esslingen, BW 73730, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.

Journal: BMC cancer
Published: June 16, 2026

Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia.

Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia.

Journal: Scientific reports
Published: February 14, 2023

Acute transverse myelitis after COVID-19 pneumonia.

Acute transverse myelitis after COVID-19 pneumonia.

Journal: Journal of neurology
Published: April 28, 2020

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).

Journal: Journal of cancer research and clinical oncology
Published: April 15, 2020

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 15, 2019

A modular transcriptome map of mature B cell lymphomas.

A modular transcriptome map of mature B cell lymphomas.

Journal: Genome medicine
Published: November 09, 2018

A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma.

A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma.

Journal: Blood
Published: January 09, 2014

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.

Journal: Haematologica
Published: November 02, 2013

High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas.

High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas.

Journal: Genes, chromosomes & cancer
Published: June 04, 2012

Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma.

Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma.

Journal: Blood
Published: January 13, 2012

Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas.

Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas.

Journal: International journal of cancer
Published: October 10, 2011
Showing 1-11 of 11

Last Updated: 09/26/2026